Avista's mission is to develop innovative gene therapies for retinal diseases, including rare, inherited conditions that have a profound impact on patients' quality of life.
We leverage our computationally guided scAAVengr platform to generate and validate a toolkit of proprietary AAV vectors that overcome the most significant obstacles to effective gene therapies, including cell-type specific delivery, reduced dosages, and efficient expression, using a minimally invasive intravitreal approach.
Our quantitative, in vivo-based approach and clinical ophthalmology expertise allow us to rapidly translate new gene therapies to the clinic.
Avista is a UPMC Enterprises portfolio company founded based on the research of Drs. Leah Byrne, Jose Sahel, and Paul Sieving.
Company Details
- Employees
- 19
- Founded
- -
- Address
- Pittsburgh, Pa, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.avistatx.com
- HQ
- Pittsburgh, PA
Avista Therapeutics Questions
Avista Therapeutics's website is http://www.avistatx.com
Avista Therapeutics's LinkedIn profile is https://www.linkedin.com/company/avista-therapeutics
Avista Therapeutics has
19 employees.
View email and phone details for 19
employees at Avista Therapeutics.
Avista Therapeutics's industry is
Biotechnology Research
Avista Therapeutics's top competitors are
Generian,
Bluesphere Bio,
Peptilogics,
Carmell Cosmetics,
Myris Therapeutics,
Spark Therapeutics, Inc.,
Cognition Therapeutics, Inc.,
Novasenta,
Noveome Biotherapeutics, Inc.,
Krystal Biotech, Inc..
Avista Therapeutics's categories are Biotechnology Research
Avista Therapeutics's founding year is 2021
